Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $8.27 million.

Sangamo Biosciences sees FY2014 revenue of $45-50 million, versus the consensus of $47.57 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.